keyword
MENU ▼
Read by QxMD icon Read
search

CIBMTR

keyword
https://www.readbyqxmd.com/read/27712033/reduced-intensity-conditioned-allograft-yields-favorable-survival-for-older-adults-with-b-cell-acute-lymphoblastic-leukemia
#1
Ashley E Rosko, Hai-Lin Wang, Marcos de Lima, Brenda Sandmaier, H Jean Khoury, Andrew Artz, Johnathan Brammer, Christopher Bredeson, Sherif Farag, Mohamed Kharfan-Dabaja, Hillard M Lazarus, David I Marks, Rodrigo Martino Bufarull, Joseph McGuirk, Mohamed Mohty, Taiga Nishihori, Ian Nivison-Smith, Armin Rashidi, Olle Ringden, Matthew Seftel, Daniel Weisdorf, Veronika Bachanova, Wael Saber
Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes. Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55-72) with B-ALL with disease status in CR1 (71%), >CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor (59%) or HLA-matched sibling (32%)...
October 6, 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27641680/effect-of-recipient-age-and-stem-cell-source-on-the-association-between-donor-telomere-length-and-survival-after-allogeneic-unrelated-hematopoietic-cell-transplantation-for-severe-aplastic-anemia
#2
Shahinaz M Gadalla, Tao Wang, Casey Dagnall, Michael Haagenson, Stephen R Spellman, Belynda Hicks, Kristine Jones, Hormuzd A Katki, Stephanie J Lee, Sharon A Savage
We previously showed an association between donor leukocyte relative telomere length (RTL) and post-hematopoietic cell transplantation (HCT) survival in patients with severe aplastic anemia (SAA) who received bone marrow grafts at ages <40 years. Here, we tested the generalizability of the prior findings in an independent validation cohort and by recipient age and stem cell source in the combined discovery and validation cohorts. We used monoplex quantitative real-time PCR to measure RTL in: (1) a new SAA validation cohort of 428 patients (age range, ...
December 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27548466/metabolic-syndrome-and-cardiovascular-disease-following-hematopoietic-cell-transplantation-screening-and-preventive-practice-recommendations-from-cibmtr-and-ebmt
#3
REVIEW
Z DeFilipp, R F Duarte, J A Snowden, N S Majhail, D M Greenfield, J L Miranda, M Arat, K S Baker, L J Burns, C N Duncan, M Gilleece, G A Hale, M Hamadani, B K Hamilton, W J Hogan, J W Hsu, Y Inamoto, R T Kamble, M T Lupo-Stanghellini, A K Malone, P McCarthy, M Mohty, M Norkin, P Paplham, M Ramanathan, J M Richart, N Salooja, H C Schouten, H Schoemans, A Seber, A Steinberg, B M Wirk, W A Wood, M Battiwalla, M E D Flowers, B N Savani, B E Shaw
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality...
August 22, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27496215/post-transplant-outcomes-in-high-risk-compared-with-non-high-risk-multiple-myeloma-a-cibmtr-analysis
#4
Emma C Scott, Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang, Dan Vogl, Muneer Abidi, Amer Beitinjaneh, Henry Fung, Siddhartha Ganguly, Gerhard Hildebrandt, Leona Holmberg, Matt Kalaycio, Shaji Kumar, Robert Kyle, Hillard Lazarus, Cindy Lee, Richard T Maziarz, Kenneth Meehan, Joseph Mikhael, Taiga Nishihori, Muthalagu Ramanathan, Saad Usmani, Jason Tay, David Vesole, Baldeep Wirk, Jean Yared, Bipin N Savani, Cristina Gasparetto, Amrita Krishnan, Tomer Mark, Yago Nieto, Anita D'Souza
Conventional cytogenetics and interphase fluorescence in situ hybridization (FISH) identify high-risk multiple myeloma (HRM) populations characterized by poor outcomes. We analyzed these differences among HRM versus non-HRM populations after upfront autologous hematopoietic cell transplantation (autoHCT). Between 2008 and 2012, 715 patients with multiple myeloma identified by FISH and/or cytogenetic data with upfront autoHCT were identified in the Center for International Blood and Marrow Transplant Research database...
October 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27315441/does-flt3-mutation-impact-survival-after-hematopoietic-stem-cell-transplantation-for-acute-myeloid-leukemia-a-center-for-international-blood-and-marrow-transplant-research-cibmtr-analysis
#5
Abhinav Deol, Salyka Sengsayadeth, Kwang Woo Ahn, Hai-Lin Wang, Mahmoud Aljurf, Joseph Harry Antin, Minoo Battiwalla, Martin Bornhauser, Jean-Yves Cahn, Bruce Camitta, Yi-Bin Chen, Corey S Cutler, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Yoshihiro Inamoto, Madan Jagasia, Rammurti Kamble, John Koreth, Hillard M Lazarus, Jane Liesveld, Mark R Litzow, David I Marks, Taiga Nishihori, Richard F Olsson, Ran Reshef, Jacob M Rowe, Ayman A Saad, Mitchell Sabloff, Harry C Schouten, Thomas C Shea, Robert J Soiffer, Geoffrey L Uy, Edmond K Waller, Peter H Wiernik, Baldeep Wirk, Ann E Woolfrey, Donald Bunjes, Steven Devine, Marcos de Lima, Brenda M Sandmaier, Dan Weisdorf, Hanna Jean Khoury, Wael Saber
BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations...
October 2016: Cancer
https://www.readbyqxmd.com/read/27220265/changing-trends-of-unrelated-umbilical-cord-blood-transplantation-for-hematologic-diseases-in-patients-older-than-fifty-years-a-eurocord-center-for-international-blood-and-marrow-transplant-research-survey
#6
Hanadi Rafii, Annalisa Ruggeri, Fernanda Volt, Claudio G Brunstein, Jeanette Carreras, Mary Eapen, Eliane Gluckman, Daniel J Weisdorf
No abstract text is available yet for this article.
September 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27184625/metabolic-syndrome-and-cardiovascular-disease-after-hematopoietic-cell-transplantation-screening-and-preventive-practice-recommendations-from-the-cibmtr-and-ebmt
#7
Zachariah DeFilipp, Rafael F Duarte, John A Snowden, Navneet S Majhail, Diana M Greenfield, José López Miranda, Mutlu Arat, K Scott Baker, Linda J Burns, Christine N Duncan, Maria Gilleece, Gregory A Hale, Mehdi Hamadani, Betty K Hamilton, William J Hogan, Jack W Hsu, Yoshihiro Inamoto, Rammurti T Kamble, Maria Teresa Lupo-Stanghellini, Adriana K Malone, Philip McCarthy, Mohamad Mohty, Maxim Norkin, Pamela Paplham, Muthalagu Ramanathan, John M Richart, Nina Salooja, Harry C Schouten, Helene Schoemans, Adriana Seber, Amir Steinberg, Baldeep M Wirk, William A Wood, Minoo Battiwalla, Mary E D Flowers, Bipin N Savani, Bronwen E Shaw
Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality...
August 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27159181/can-we-agree-on-patient-reported-outcome-measures-for-assessing-hematopoietic-cell-transplantation-patients-a-study-from-the-cibmtr-and-bmt-ctn
#8
REVIEW
B E Shaw, S J Lee, M M Horowitz, W A Wood, J D Rizzo, K E Flynn
Much research into the impact of hematopoietic cell transplantation (HCT) on recipients' symptoms, functioning and health-related quality of life uses diverse patient-reported outcome (PRO) measures. Robust conclusions regarding PROs in HCT patients are constrained by methodological issues, including the use of multiple different and noncomparable assessment measures. We reviewed 114 publications addressing PROs in HCT patients. Although three multi-item measures were most frequently used (FACT-BMT, n=28; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, n=26; and SF-36, n=26), 25 additional measures were used in more than one study...
September 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27108694/defibrotide-for-treatment-of-severe-veno-occlusive-disease-in-pediatrics-and-adults-an-exploratory-analysis-using-data-from-the-center-for-international-blood-and-marrow-transplant-research
#9
Christopher Strouse, Paul Richardson, Grant Prentice, Sandra Korman, Robin Hume, Bijan Nejadnik, Mary M Horowitz, Wael Saber
Veno-occlusive disease (VOD) is an early and serious complication of hematopoietic cell transplantation (HCT) that is associated with inferior survival, particularly when it is complicated by multiorgan failure (severe VOD). We evaluated the efficacy of defibrotide in the treatment of severe VOD using observational data from the Center for International Blood and Marrow Transplant Research (CIBMTR). Eight thousand three hundred forty-one patients treated by HCT between 2008 and 2011 were identified from the CIBMTR clinical database; 3...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27090960/the-impact-of-palifermin-use-on-hematopoietic-cell-transplant-outcomes-in-children
#10
Wael Saber, Mei-Jie Zhang, Patricia Steinert, Min Chen, Mary M Horowitz
Clinical trials evaluating palifermin have enrolled few pediatric patients, precluding safety analyses in large groups of children. We compared hematopoietic cell transplantation (HCT) outcomes among pediatric patients who did or did not receive palifermin as a preventive treatment for oral mucositis. Pediatric patients and controls, matched for HCT and donor type, disease, disease status, and age, were selected from the Center for International Blood and Marrow Transplant Research database and a 1:3 matched cohort analysis was performed...
August 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27088379/autologous-transplant-remains-the-preferred-therapy-for-relapsed-apl-in-cr2
#11
C Ganzel, V Mathews, K Alimoghaddam, A Ghavamzadeh, D Kuk, S Devlin, H Wang, M-J Zhang, D Weisdorf, D Douer, J M Rowe, E Polge, J Esteve, A Nagler, M Mohty, M S Tallman
Despite their favorable prognosis, 10-20% of acute promyelocytic leukemia (APL) patients relapse. Reinduction therapy is often followed by autologous hematopoietic cell transplantation (auto-HCT). Arsenic trioxide (ATO) has become part of standard reinduction and is often followed by auto-HCT. Data on patients in CR2 were collected from two large transplant registries (Center for International Blood and Marrow Transplant Research (CIBMTR) and European Group for Blood and Marrow Transplant (EBMT)) and two specialty referral centers...
September 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27040394/efficacy-of-pharmacokinetics-directed-busulfan-cyclophosphamide-and-etoposide-conditioning-and-autologous-stem-cell-transplantation-for-lymphoma-comparison-of-a-multicenter-phase-ii-study-and-cibmtr-outcomes
#12
Christopher R Flowers, Luciano J Costa, Marcelo C Pasquini, Jennifer Le-Rademacher, Michael Lill, Tsiporah B Shore, William Vaughan, Michael Craig, Cesar O Freytes, Thomas C Shea, Mitchell E Horwitz, Joseph W Fay, Shin Mineishi, Damiano Rondelli, James Mason, Ira Braunschweig, Weiyun Ai, Rosa F Yeh, Tulio E Rodriguez, Ian Flinn, Terrance Comeau, Andrew M Yeager, Michael A Pulsipher, Isabelle Bence-Bruckler, Pierre Laneuville, Philip Bierman, Andy I Chen, Kazunobu Kato, Yanlin Wang, Cong Xu, Angela J Smith, Edmund K Waller
Busulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen for autologous stem cell transplantation (ASCT). This multicenter, phase II study examined the safety and efficacy of BuCyE with individually adjusted busulfan based on preconditioning pharmacokinetics. The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years. BuCyE outcomes were compared with contemporaneous recipients of carmustine, etoposide, cytarabine, and melphalan (BEAM) from the Center for International Blood and Marrow Transplant Research...
July 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27034534/a-proportional-hazards-regression-model-for-the-sub-distribution-with-covariates-adjusted-censoring-weight-for-competing-risks-data
#13
Peng He, Frank Eriksson, Thomas H Scheike, Mei-Jie Zhang
With competing risks data, one often needs to assess the treatment and covariate effects on the cumulative incidence function. Fine and Gray proposed a proportional hazards regression model for the subdistribution of a competing risk with the assumption that the censoring distribution and the covariates are independent. Covariate-dependent censoring sometimes occurs in medical studies. In this paper, we study the proportional hazards regression model for the subdistribution of a competing risk with proper adjustments for covariate-dependent censoring...
March 2016: Scandinavian Journal of Statistics, Theory and Applications
https://www.readbyqxmd.com/read/26989808/allogeneic-transplantation-provides-durable-remission-in-a-subset-of-dlbcl-patients-relapsing-after-autologous-transplantation
#14
Timothy S Fenske, Kwang W Ahn, Tara M Graff, Alyssa DiGilio, Qaiser Bashir, Rammurti T Kamble, Ernesto Ayala, Ulrike Bacher, Jonathan E Brammer, Mitchell Cairo, Andy Chen, Yi-Bin Chen, Saurabh Chhabra, Anita D'Souza, Umar Farooq, Cesar Freytes, Siddhartha Ganguly, Mark Hertzberg, David Inwards, Samantha Jaglowski, Mohamed A Kharfan-Dabaja, Hillard M Lazarus, Sunita Nathan, Attaphol Pawarode, Miguel-Angel Perales, Nishitha Reddy, Sachiko Seo, Anna Sureda, Sonali M Smith, Mehdi Hamadani
For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival (OS) were 30, 38, 31 and 37% respectively...
July 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26964698/outcomes-of-allogeneic-hematopoietic-cell-transplantation-in-children-and-young-adults-with-chronic-myeloid-leukemia-a-cibmtr-cohort-analysis
#15
Sonali Chaudhury, Rodney Sparapani, Zhen-Huan Hu, Taiga Nishihori, Hisham Abdel-Azim, Adriana Malone, Richard Olsson, Mehdi Hamadani, Andrew Daly, Ulrike Bacher, Baldeep M Wirk, Rammurti T Kamble, Robert P Gale, William A Wood, Gregory Hale, Peter H Wiernik, Shahrukh K Hashmi, David Marks, Celalettin Ustun, Reinhold Munker, Bipin N Savani, Edwin Alyea, Uday Popat, Ronald Sobecks, Matt Kalaycio, Richard Maziarz, Nobuko Hijiya, Wael Saber
Chronic myeloid leukemia (CML) in children and young adults is uncommon. Young patients have long life expectancies and low morbidity with hematopoietic cell transplantation (HCT). Prolonged tyrosine kinase inhibitor (TKI) use may cause significant morbidity. In addition, indication for HCT in patients in the first chronic phase is not established. We hence retrospectively evaluated outcomes in 449 CML patients with early disease receiving myeloablative HCT reported to the CIBMTR. We analyzed various factors affecting outcome, specifically the effect of age and pre-HCT TKI in pediatric patients (age < 18 years, n = 177) and young adults (age 18 to 29 years, n = 272) with the goal of identifying prognostic factors...
June 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/26884374/early-cytomegalovirus-reactivation-remains-associated-with-increased-transplant-related-mortality-in-the-current-era-a-cibmtr-analysis
#16
Pierre Teira, Minoo Battiwalla, Muthalagu Ramanathan, A John Barrett, Kwang Woo Ahn, Min Chen, Jaime S Green, Ayman Saad, Joseph H Antin, Bipin N Savani, Hillard M Lazarus, Matthew Seftel, Wael Saber, David Marks, Mahmoud Aljurf, Maxim Norkin, John R Wingard, Caroline A Lindemans, Michael Boeckh, Marcie L Riches, Jeffery J Auletta
Single-center studies have reported an association between early (before day 100) cytomegalovirus (CMV) reactivation and decreased incidence of relapse for acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation. To substantiate these preliminary findings, the Center for International Blood and Marrow Transplant Research (CIBMTR) Database was interrogated to analyze the impact of CMV reactivation on hematologic disease relapse in the current era. Data from 9469 patients transplanted with bone marrow or peripheral blood between 2003 and 2010 were analyzed according to 4 disease categories: AML (n = 5310); acute lymphoblastic leukemia (ALL, n = 1883); chronic myeloid leukemia (CML, n = 1079); and myelodysplastic syndrome (MDS, n = 1197)...
May 19, 2016: Blood
https://www.readbyqxmd.com/read/26838373/risk-factors-and-impact-of-non-aspergillus-mold-infections-following-allogeneic-hct-a-cibmtr-infection-and-immune-reconstitution-analysis
#17
M L Riches, S Trifilio, M Chen, K W Ahn, A Langston, H M Lazarus, D I Marks, R Martino, R T Maziarz, G A Papanicolou, J R Wingard, J-Ah Young, C L Bennett
No abstract text is available yet for this article.
February 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/26726945/the-incidence-mortality-and-timing-of-pneumocystis-jiroveci-pneumonia-after-hematopoietic-cell-transplantation-a-cibmtr-analysis
#18
K M Williams, K W Ahn, M Chen, M D Aljurf, A L Agwu, A R Chen, T J Walsh, P Szabolcs, M J Boeckh, J J Auletta, C A Lindemans, J Zanis-Neto, M Malvezzi, J Lister, J S de Toledo Codina, K Sackey, J L H Chakrabarty, P Ljungman, J R Wingard, M D Seftel, S Seo, G A Hale, B Wirk, M S Smith, B N Savani, H M Lazarus, D I Marks, C Ustun, H Abdel-Azim, C C Dvorak, J Szer, J Storek, A Yong, M R Riches
Pneumocystis jiroveci pneumonia (PJP) is associated with high morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Little is known about PJP infections after HSCT because of the rarity of disease given routine prophylaxis. We report the results of a Center for International Blood and Marrow Transplant Research study evaluating the incidence, timing, prophylaxis agents, risk factors and mortality of PJP after autologous (auto) and allogeneic (allo) HSCT. Between 1995 and 2005, 0.63% allo recipients and 0...
April 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/26701142/pediatric-inspired-therapy-compared-to-allografting-for-philadelphia-chromosome-negative-adult-all-in-first-complete-remission
#19
COMPARATIVE STUDY
Matthew D Seftel, Donna Neuberg, Mei-Jie Zhang, Hai-Lin Wang, Karen Kuhn Ballen, Julie Bergeron, Stephen Couban, César O Freytes, Mehdi Hamadani, Mohamed A Kharfan-Dabaja, Hillard M Lazarus, Taiga Nishihori, Kristjan Paulson, Wael Saber, Stephen E Sallan, Robert Soiffer, Martin S Tallman, Ann E Woolfrey, Daniel J DeAngelo, Daniel J Weisdorf
For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen...
March 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/26597080/significant-improvements-in-the-practice-patterns-of-adult-related-donor-care-in-us-transplantation-centers
#20
MULTICENTER STUDY
Chloe Anthias, Bronwen E Shaw, Deidre M Kiefer, Jane L Liesveld, Jean Yared, Rammurti T Kamble, Anita D'Souza, Peiman Hematti, Matthew D Seftel, Maxim Norkin, Zachariah DeFilipp, Kimberly A Kasow, Muneer H Abidi, Bipin N Savani, Nirali N Shah, Paolo Anderlini, Miguel A Diaz, Adriana K Malone, Joerg P Halter, Hillard M Lazarus, Brent R Logan, Galen E Switzer, Michael A Pulsipher, Dennis L Confer, Paul V O'Donnell
Recent investigations have found a higher incidence of adverse events associated with hematopoietic cell donation in related donors (RDs) who have morbidities that if present in an unrelated donor (UD) would preclude donation. In the UD setting, regulatory standards ensure independent assessment of donors, one of several crucial measures to safeguard donor health and safety. A survey conducted by the Center for International Blood and Marrow Transplant Research (CIBMTR) Donor Health and Safety Working Committee in 2007 reported a potential conflict of interest in >70% of US centers, where physicians had simultaneous responsibility for RDs and their recipients...
March 2016: Biology of Blood and Marrow Transplantation
keyword
keyword
115199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"